share_log

Oncorus, Inc. (NASDAQ:ONCR) Major Shareholder James E. Flynn Sells 99,718 Shares

Oncorus, Inc. (NASDAQ:ONCR) Major Shareholder James E. Flynn Sells 99,718 Shares

安科力斯股份有限公司 (NASDAQ: ONCR) 主要股東詹姆斯·弗林出售 99,718 股股份
kopsource ·  2022/12/21 21:31

Oncorus, Inc. (NASDAQ:ONCR – Get Rating) major shareholder James E. Flynn sold 99,718 shares of the business's stock in a transaction that occurred on Monday, December 19th. The shares were sold at an average price of $0.29, for a total transaction of $28,918.22. Following the completion of the sale, the insider now directly owns 332,725 shares in the company, valued at $96,490.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.

安科魯斯股份有限公司（NASDAQ：ONCR-獲得評級）主要股東詹姆斯 ·E· 弗林在 12 月 19 日（星期一）進行的交易中出售了該企業股票的 99,718 股。這些股票以 0.29 美元的平均價格出售，總交易額為 28,918.22 美元。出售完成後，內幕人士目前直接擁有該公司 332,725 股股份，價值 96,490.25 美元。該交易在與 SEC 合法提交的文件中披露，該文件可通過以下方式訪問 證券交易所網站。擁有公司股票 10％ 或以上的主要股東必須披露其與 SEC 的交易。

Oncorus Stock Down 8.3 %

安科洛斯股票下降 8.3%

ONCR traded down $0.03 during trading hours on Wednesday, hitting $0.28. 86,612 shares of the company's stock were exchanged, compared to its average volume of 130,208. Oncorus, Inc. has a 12-month low of $0.27 and a 12-month high of $5.76. The firm has a 50 day moving average of $0.57 and a 200 day moving average of $1.04. The firm has a market cap of $7.27 million, a P/E ratio of -0.10 and a beta of 2.24. The company has a current ratio of 4.97, a quick ratio of 4.97 and a debt-to-equity ratio of 0.24.

ONCR 周三交易時間下跌 0.03 美元，觸及 0.28 美元。該公司股票的 86,612 股被交換，相比其平均交易量為 130,208 股。安科力斯擁有 12 個月低點 0.27 美元和 12 個月高點為 5.76 美元。該公司的 50 日移動平均線為 0.57 美元，200 日移動平均線為 1.04 美元。該公司的市值為 727 萬美元，市盈率為 -0.10，測試版為 2.24。該公司的流動比率為 4.97，快速比率為 4.97，債務與權益比率為 0.24。

Get
取得
Oncorus
翁科洛斯
alerts:
警報：

Oncorus (NASDAQ:ONCR – Get Rating) last posted its quarterly earnings results on Wednesday, November 2nd. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.77) by $0.01. Analysts predict that Oncorus, Inc. will post -2.69 EPS for the current fiscal year.

Oncorus (NASDAQ: ONCR-獲取評分) 上次公佈其季度收益業績於 11 月 2 日星期三。該公司報告了本季每股盈利（0.76 美元），超過 0.01 美元的共識估計（0.77 美元）。分析師預測，安科洛斯公司將在當前財政年度發布 -2.69 每股盈利。

Institutional Inflows and Outflows

機構流入和流出

Several institutional investors and hedge funds have recently added to or reduced their stakes in ONCR. Millennium Management LLC acquired a new position in Oncorus during the 2nd quarter worth approximately $476,000. Renaissance Technologies LLC boosted its holdings in shares of Oncorus by 1,144.9% in the 1st quarter. Renaissance Technologies LLC now owns 175,532 shares of the company's stock valued at $312,000 after buying an additional 161,432 shares in the last quarter. Private Advisor Group LLC acquired a new position in shares of Oncorus in the 1st quarter valued at $112,000. Bank of New York Mellon Corp boosted its holdings in shares of Oncorus by 106.6% in the 1st quarter. Bank of New York Mellon Corp now owns 122,047 shares of the company's stock valued at $218,000 after buying an additional 62,985 shares in the last quarter. Finally, Sawtooth Solutions LLC acquired a new position in shares of Oncorus in the 1st quarter valued at $112,000. Institutional investors and hedge funds own 65.89% of the company's stock.
幾家機構投資者和對沖基金最近增加或減少了他們在 ONCR 的股份。千禧管理有限責任公司在第二季度收購了昂科洛斯的新職位，價值約為 476,000 美元。文藝復興技術有限責任公司在第一季度將其在安科魯斯股份的持有量提高了 1,144.9％。復興科技有限責任公司現在擁有該公司股票的 175,532 股價值 312,000 美元，在上一季度額外購買 161,432 股股票後。私人顧問集團有限責任公司在第一季度收購了 Oncorus 股份的新職位，價值為 112,000 美元。紐約梅隆銀行第一季度將其在安科洛斯股份的持有量提高了 106.6％。紐約梅隆銀行在上一季度額外購買 62,985 股股後，現在擁有該公司股票的 122,047 股價值為 218,000 美元。最後，鋸齒解決方案有限責任公司在第一季度收購了價值 112,000 美元的 Oncorus 股份的新位置。機構投資者和對沖基金擁有公司股票的 65.89%。

Analyst Upgrades and Downgrades

分析師升級和降級

A number of equities research analysts have recently issued reports on the stock. Piper Sandler downgraded shares of Oncorus from an "overweight" rating to a "neutral" rating and reduced their price target for the company from $6.00 to $2.00 in a research note on Wednesday, November 30th. Chardan Capital downgraded shares of Oncorus from a "buy" rating to a "neutral" rating in a research note on Wednesday, November 30th. Finally, HC Wainwright downgraded shares of Oncorus from a "buy" rating to a "neutral" rating in a research note on Tuesday, December 6th.

一些股票研究分析師最近發表了有關該股票的報告。派珀·桑德勒（Piper Sandler）將 Oncorus 的股票從「超重」評級降級為「中性」評級，並在 11 月 30 日（星期三）的一份研究報告中將公司的目標價格從 6.00 美元降至 2.00 美元。在 11 月 30 日（週三）的研究報告中，Chardan 資本將 Oncorus 的股票從「買入」評級降級為「中性」評級。最後，在 12 月 6 日（星期二）的研究報告中，HC 溫賴特將安科洛斯的股票從「買入」評級降級為「中性」評級。

Oncorus Company Profile

安科力斯公司簡介

(Get Rating)

(取得評分)

Oncorus, Inc, a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers.

Oncorus, Inc 是一家臨床階段生物製藥公司，致力於為癌症患者開發病毒免疫療法。該公司的主要候選產品是 ONCR-177，這是一種基於其單純皰疹病毒 1 型平台的臨床內施用的病毒免疫療法，該平台正在用於治療各種癌症的 I 期臨床試驗中。

Read More

閱讀更多

  • Get a free copy of the StockNews.com research report on Oncorus (ONCR)
  • Institutions Put Bottom In Rite Aid Shares
  • Here's Why You Should Steer Clear of the FedEx Bounce
  • Why Did Viking Therapeutics Stock Skyrocket
  • NIKE, Inc Swooshes Higher On Results And Outlook
  • Will AMC's Troubles Affect Its Landlord, EPR Properties?
  • 免費獲取有關安科洛斯（ONCR）的研究報告
  • 機構將儀式援助股份置於底
  • 這就是為什麼您應該避開聯邦快遞反彈
  • 為什麼維京療法股票暴漲
  • 耐克公司標誌設計較高的結果和展望
  • AMC 的麻煩會影響其房東，EPR 物業嗎？

Receive News & Ratings for Oncorus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncorus and related companies with MarketBeat.com's FREE daily email newsletter.

接收 Oncorus 日報的最新消息和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Oncorus 及相關公司的最新新聞和分析師評級的簡要每日摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論